NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
Clinical Trials
21 trialsNCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT03386929 2023-12-18
SPRING
Worldwide Innovative Network Association
Phase 1/2 Terminated
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05249569 2023-05-03
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT01385059 2023-03-07
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT02762513 2021-05-05
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01321437 2021-01-20
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
University of California, Irvine
Phase 2 Completed
NCT01490866 2019-09-24
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01435122 2018-10-02
A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01174238 2018-06-08
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT01533948 2018-05-09
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01558661 2017-11-28
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01508117 2017-09-19
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
University of Cincinnati
Phase 2 Terminated